LIGAND PHARMACEUTICALS INC 8K

Ligand Pharmaceuticals completed its $739 million cash acquisition of XOMA Royalty Corporation, more than doubling its royalty portfolio and projecting immediate accretion to adjusted EPS in 2026 and 2027.

Ligand Pharmaceuticals Incorporated announced that it has completed its acquisition of XOMA Royalty Corporation, a biotechnology royalty aggregator, for $39.00 per share in cash, representing total equity value of approximately $739 million, with XOMA Royalty stockholders also receiving a non-transferable contingent value right tied to 75% of net proceeds from certain pending litigation. The transaction more than doubles Ligand’s royalty portfolio to over 200 commercial, clinical, and preclinical royalty assets, including seven commercial products such as Roche’s VABYSMO, Servier’s OJEMDA, and Zevra Therapeutics’ MIPLYFFA, plus 14 late-stage development programs and more than 100 additional development-stage assets. Ligand expects the acquisition to be immediately accretive, projecting it will add approximately $0.50 and $1.50 per share to its 2026 and 2027 adjusted earnings per share, respectively, and plans to provide an updated five-year outlook at its Investor Day on December 8, 2026. In connection with the closing, XOMA Royalty’s common stock ceased trading on The Nasdaq Global Market, and both companies disclosed typical integration, litigation, and regulatory risks associated with the transaction.

Filing Facts

CIK

886163

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-302660

Alert Tier

8